IL228862D0 - Fused imidazole derivatives useful as ido inhibitors - Google Patents

Fused imidazole derivatives useful as ido inhibitors

Info

Publication number
IL228862D0
IL228862D0 IL228862A IL22886213A IL228862D0 IL 228862 D0 IL228862 D0 IL 228862D0 IL 228862 A IL228862 A IL 228862A IL 22886213 A IL22886213 A IL 22886213A IL 228862 D0 IL228862 D0 IL 228862D0
Authority
IL
Israel
Prior art keywords
treating
dioxygenase
indoleamine
ido inhibitors
imidazole derivatives
Prior art date
Application number
IL228862A
Other languages
Hebrew (he)
Other versions
IL228862A (en
Original Assignee
Newlink Genetics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201161475788P priority Critical
Priority to PCT/US2012/033245 priority patent/WO2012142237A1/en
Application filed by Newlink Genetics Corp filed Critical Newlink Genetics Corp
Publication of IL228862D0 publication Critical patent/IL228862D0/en
Publication of IL228862A publication Critical patent/IL228862A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

Presently provided are IDO inhibitors and pharmaceutical compositions thereof, useful for modulating an activity of indoleamine 2,3-dioxygenase; treating indoleamine 2,3-dioxygenase (IDO) mediated inimunosuppression; treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; treating tumor-specific immunosuppression associated with cancer; and treating immunosupression associated with an infectious disease.
IL228862A 2011-04-15 2013-10-14 נגזרות אימידאזול ממוזגות לשימוש כמונעי ido IL228862A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US201161475788P true 2011-04-15 2011-04-15
PCT/US2012/033245 WO2012142237A1 (en) 2011-04-15 2012-04-12 Fused imidazole derivatives useful as ido inhibitors

Publications (2)

Publication Number Publication Date
IL228862D0 true IL228862D0 (en) 2013-12-31
IL228862A IL228862A (en) 2015-10-29

Family

ID=45976556

Family Applications (3)

Application Number Title Priority Date Filing Date
IL228862A IL228862A (en) 2011-04-15 2013-10-14 נגזרות אימידאזול ממוזגות לשימוש כמונעי ido
IL241846A IL241846A (en) 2011-04-15 2015-09-24 Fused imidazole derivatives useful as ido inhibitors
IL246515A IL246515A (en) 2011-04-15 2016-06-28 Fused imidazole derivatives useful as ido inhibitors

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL241846A IL241846A (en) 2011-04-15 2015-09-24 Fused imidazole derivatives useful as ido inhibitors
IL246515A IL246515A (en) 2011-04-15 2016-06-28 Fused imidazole derivatives useful as ido inhibitors

Country Status (30)

Country Link
US (4) US9260434B2 (en)
EP (3) EP2697227B1 (en)
JP (4) JP2014511876A (en)
KR (1) KR20140059167A (en)
CN (2) CN105111210B (en)
AU (4) AU2012242871C1 (en)
BR (1) BR112013026494A2 (en)
CA (1) CA2833296A1 (en)
CL (1) CL2013002990A1 (en)
CO (1) CO6862146A2 (en)
CY (1) CY1117440T1 (en)
DK (2) DK3018132T3 (en)
ES (2) ES2660831T3 (en)
HK (2) HK1193822A1 (en)
HR (2) HRP20160369T1 (en)
HU (2) HUE027316T2 (en)
IL (3) IL228862A (en)
LT (1) LT3018132T (en)
ME (1) ME02417B (en)
MX (1) MX340442B (en)
NO (1) NO2694640T3 (en)
NZ (3) NZ723271A (en)
PE (2) PE11242014A1 (en)
PL (2) PL3018132T3 (en)
PT (1) PT3018132T (en)
RS (2) RS54723B1 (en)
RU (2) RU2017107026A3 (en)
SI (2) SI2697227T1 (en)
SM (1) SMT201600130B (en)
WO (1) WO2012142237A1 (en)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2694640T3 (en) 2011-04-15 2018-03-17
WO2014159248A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
BR112015022575A2 (en) 2013-03-14 2017-07-18 Curadev Pharma Private Ltd compound of formula prodrug of a compound, kit, method for adjusting a path to adjust any one or more of enzymes to reduce metabolites to alter tryptophan levels, to treat immune suppression, to reduce or eliminate an immune-mediated disorder , to inhibit the activation of enzymes to treat a disease, to inhibit a production of autoimmune antibody, to prepare a compound and to diagnose and treat a disease compound and obtainable by a method
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN103382187B (en) * 2013-08-06 2015-06-03 信实生物医药(上海)有限公司 3-chloro-7(5)-bromo-benzo-isoxazole compounding method
SI3087071T1 (en) 2013-12-24 2018-11-30 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
CA2951234A1 (en) 2014-06-06 2015-12-10 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
KR20170044144A (en) * 2014-09-05 2017-04-24 메르크 파텐트 게엠베하 Cyclohexyl-ethyl substituted diaza- and triaza-tricyclic compounds as indole-amine-2,3-dioxygenase (ido) antagonists for the treatment of cancer
GB201417369D0 (en) * 2014-10-01 2014-11-12 Redx Pharma Ltd Compounds
GB201418300D0 (en) * 2014-10-15 2014-11-26 Redx Pharma Ltd Compounds
TW201625693A (en) 2014-11-21 2016-07-16 Squibb Bristol Myers Co Antibodies against CD73 and uses thereof
TW201630907A (en) 2014-12-22 2016-09-01 Squibb Bristol Myers Co TGF[beta]R antagonists
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
CN105884828A (en) * 2015-02-16 2016-08-24 上海迪诺医药科技有限公司 Polycyclic compound, pharmaceutical composition and application thereof
CA2973602A1 (en) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. Tgf-.beta. inhibitors
TW201700453A (en) 2015-04-03 2017-01-01 Bristol-Myers Squibb Company IDO inhibitors
TW201642897A (en) 2015-04-08 2016-12-16 Star Biotechnology Ltd F HER2 binding agent therapies
US10280163B2 (en) 2015-04-10 2019-05-07 Beigene, Ltd. 5 or 8-substituted imidazo[1, 5-a] pyridines as indoleamine and/or tryptophane 2, 3-dioxygenases
CN108026098A (en) * 2015-04-12 2018-05-11 杭州英创医药科技有限公司 Heterocycles useful as ido and tdo inhibitors
KR20170135924A (en) 2015-04-13 2017-12-08 파이브 프라임 테라퓨틱스, 인크. Combination Therapy for Cancer
MX2017013310A (en) * 2015-04-21 2018-02-26 Jiangsu Hengrui Medicine Co Imidazo isoindole derivative, preparation method therefor and medical use thereof.
US20180127413A1 (en) 2015-05-11 2018-05-10 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US10174024B2 (en) 2015-05-12 2019-01-08 Bristol-Myers Squibb Company 5H-pyrido[3,2-B]indole compounds as anticancer agents
AU2016271111A1 (en) 2015-05-29 2017-12-07 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
GB2548542A (en) * 2015-06-16 2017-09-27 Redx Pharma Plc Compounds
CN106256830B (en) * 2015-06-18 2019-03-08 成都海创药业有限公司 A kind of deuterated IDO inhibitor and its preparation method and application
CA2990015A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
CN105037371A (en) * 2015-06-30 2015-11-11 西华大学 Deuterated indoleamine-2,3-dioxygenase inhibitor
GB201511790D0 (en) * 2015-07-06 2015-08-19 Iomet Pharma Ltd Pharmaceutical compound
CN107921087A (en) 2015-07-16 2018-04-17 百欧肯治疗有限公司 Compositions and methods for treating cancer
KR20180030825A (en) 2015-07-24 2018-03-26 뉴링크 제네틱스 코퍼레이션 Salt of 1-methyl-tryptophan and -d- prodrug
JP2018526344A (en) 2015-07-28 2018-09-13 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Tgf beta receptor antagonist
EP3341372A1 (en) 2015-08-25 2018-07-04 Bristol-Myers Squibb Company Tgf beta receptor antagonists
CN106478634A (en) * 2015-09-01 2017-03-08 上海璎黎药业有限公司 Condensed imidazole compound and preparation method, pharmaceutical composition and use thereof
WO2017075341A1 (en) * 2015-10-29 2017-05-04 Scifluor Life Sciences, Inc. Fused imidazole derivatives as ido/tdo inhibitors
WO2017079117A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
KR20180081606A (en) 2015-11-23 2018-07-16 파이브 프라임 테라퓨틱스, 인크. FGFR2 inhibitor alone or in combination with an immunostimulant in cancer therapy
EP3390406A1 (en) 2015-12-15 2018-10-24 Bristol-Myers Squibb Company Cxcr4 receptor antagonists
WO2017107979A1 (en) * 2015-12-24 2017-06-29 Genentech, Inc. Tdo2 inhibitors
EP3400226A1 (en) 2016-02-02 2018-11-14 Emcure Pharmaceuticals Limited Derivatives of pyrroloimidazole or analogues thereof which are useful for the treatment of inter alia cancer
EP3416725A1 (en) 2016-02-19 2018-12-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of obesity
CN108884104A (en) * 2016-02-19 2018-11-23 正大天晴药业集团股份有限公司 Tricyclic compound acting as immunomodulator
CA3015012A1 (en) * 2016-02-19 2017-08-24 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tricyclic compound serving as immunomodulator
WO2017149469A1 (en) 2016-03-03 2017-09-08 Emcure Pharmaceuticals Limited Heterocyclic compounds useful as ido and/or tdo modulators
CN109476740A (en) 2016-03-04 2019-03-15 百时美施贵宝公司 Utilize the combination therapy of anti-CD73 antibody
CN105732643A (en) * 2016-04-18 2016-07-06 苏州大学 Conjugate and preparation method thereof and application to preparation of IDO enzyme inhibitor and non-steroidal anti-inflammatory drugs
US20180066053A1 (en) 2016-04-18 2018-03-08 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
CN107312005A (en) * 2016-04-27 2017-11-03 上海翰森生物医药科技有限公司 Fused imidazole derivative having IDO/TDO inhibition activity and having structure represented by formula (I), preparation method and applications thereof
EP3452452A1 (en) 2016-05-04 2019-03-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN105902542A (en) * 2016-05-16 2016-08-31 张阳 Application of conjugate in preparation of medicine for treating cardiovascular diseases
WO2017198159A1 (en) * 2016-05-16 2017-11-23 鲁南制药集团股份有限公司 Imidazole derivative containing bridge ring
CN106957318A (en) * 2016-05-19 2017-07-18 中国科学院上海有机化学研究所 Fused polycyclic indoline compound and preparation method thereof as well as pharmaceutical composition and application
AR108586A1 (en) 2016-06-10 2018-09-05 Lilly Co Eli Compounds of 2,3-dihydro-1H-indole
SG11201900026TA (en) 2016-07-14 2019-01-30 Squibb Bristol Myers Co Antibodies against tim3 and uses thereof
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
WO2018028491A1 (en) * 2016-08-09 2018-02-15 苏州国匡医药科技有限公司 Indoleamine2,3-dioxygenase inhibitors and uses thereof in pharmacy
WO2018045966A1 (en) * 2016-09-12 2018-03-15 广州必贝特医药技术有限公司 Imidazole-containing fused tricyclic compounds and applications thereof
SG11201903282TA (en) 2016-10-13 2019-05-30 Juno Therapeutics Inc Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
WO2018072743A1 (en) * 2016-10-21 2018-04-26 苏州盛迪亚生物医药有限公司 Use of pd-1 antibody conjugated with ido inhibitor in preparing anti-tumor drug
TW201815793A (en) * 2016-10-21 2018-05-01 Jiangsu hengrui medicine co ltd Crystalline form of free alkali of imidazo isoindole derivative and a preparation method thereof
CN106474468A (en) * 2016-11-23 2017-03-08 中国医学科学院医学生物学研究所 Composite adjuvant, vaccine comprising the same and preparation method of vaccine
WO2018106579A1 (en) * 2016-12-06 2018-06-14 Albert Einstein College Of Medicine, Inc. Drug targeting of human indoleamine 2,3-dioxygenase
AU2017382405A1 (en) 2016-12-22 2019-06-27 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
WO2018132279A1 (en) 2017-01-05 2018-07-19 Bristol-Myers Squibb Company Tgf beta receptor antagonists
WO2018175954A1 (en) 2017-03-23 2018-09-27 F. Hoffmann-La Roche Ag Synthesis of imidazo[5,1-a]isoindole derivative useful as ido inhibitors
WO2018183608A1 (en) 2017-03-31 2018-10-04 Five Prime Therapeutics, Inc. Combination therapy for cancer using anti-gitr antibodies
TW201843173A (en) 2017-04-07 2018-12-16 美商必治妥美雅史谷比公司 Anti icos agonist antibodies and uses thereof
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
WO2018209049A1 (en) 2017-05-12 2018-11-15 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN107176956A (en) * 2017-05-31 2017-09-19 成都海博锐药业有限公司 IDO inhibitor compound, pharmaceutical compound and application
WO2019005559A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019006047A1 (en) 2017-06-28 2019-01-03 Genentech, Inc. Tdo2 and ido1 inhibitors
WO2019023459A1 (en) 2017-07-28 2019-01-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019029507A1 (en) * 2017-08-08 2019-02-14 江苏恒瑞医药股份有限公司 Preparation method for imidazoisoindole derivatives
WO2019034725A1 (en) 2017-08-17 2019-02-21 Idorsia Pharmaceuticals Ltd Inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan 2,3-dioxygenase
WO2019046496A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046500A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019046498A1 (en) 2017-08-31 2019-03-07 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CN107501272A (en) * 2017-09-05 2017-12-22 中国药科大学 Imidazo isoindole IDO1 inhibitor as well as preparation method and application thereof
WO2019074822A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20190144549A1 (en) 2017-10-10 2019-05-16 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
WO2019089921A1 (en) 2017-11-01 2019-05-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126713B1 (en) 1983-05-18 1989-01-18 Ciba-Geigy Ag Cyclohexanedione-carboxylic-acid derivatives having a herbicidal and plant growth regulating activity
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
AU2002307243B2 (en) 2002-04-12 2008-01-03 Medical College Of Georgia Research Institute, Inc. Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
US7714139B2 (en) 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
US7598287B2 (en) 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
EP1730148A4 (en) 2004-02-03 2009-08-19 Abbott Lab Aminobenzoxazoles as therapeutic agents
ES2578404T3 (en) * 2005-05-10 2016-07-26 Incyte Holdings Corporation Modulators indoleamine 2,3 dioxygenase, and methods of use thereof
US7705022B2 (en) 2005-10-27 2010-04-27 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
ES2540561T3 (en) 2005-12-20 2015-07-10 Incyte Corporation N-hidroxiamidinoheterociclos as modulators of indoleamine 2,3 dioxygenase
US8389568B2 (en) 2007-03-16 2013-03-05 Lankenau Institute For Medical Research IDO inhibitors and methods of use thereof
DE102007020493A1 (en) 2007-04-30 2008-11-06 Grünenthal GmbH Substituted amide derivatives
EP2227233B1 (en) 2007-11-30 2013-02-13 Newlink Genetics Ido inhibitors
JP5537439B2 (en) 2007-12-19 2014-07-02 アムジエン・インコーポレーテツド Fused pyridine as a cell cycle inhibitor, pyrimidine and triazine compounds
JP2011518841A (en) * 2008-04-24 2011-06-30 ニューリンク ジェネティクス, インコーポレイテッド Ido inhibitors
EA029781B1 (en) 2008-07-08 2018-05-31 Инсайт Корпорейшн 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase
WO2011056652A1 (en) 2009-10-28 2011-05-12 Newlink Genetics Imidazole derivatives as ido inhibitors
NO2694640T3 (en) * 2011-04-15 2018-03-17
US9073875B2 (en) 2012-11-20 2015-07-07 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of indoleamine 2,3-dioxygenase
BR112015022575A2 (en) 2013-03-14 2017-07-18 Curadev Pharma Private Ltd compound of formula prodrug of a compound, kit, method for adjusting a path to adjust any one or more of enzymes to reduce metabolites to alter tryptophan levels, to treat immune suppression, to reduce or eliminate an immune-mediated disorder , to inhibit the activation of enzymes to treat a disease, to inhibit a production of autoimmune antibody, to prepare a compound and to diagnose and treat a disease compound and obtainable by a method
WO2014141110A2 (en) 2013-03-14 2014-09-18 Curadev Pharma Pvt. Ltd. Aminonitriles as kynurenine pathway inhibitors
WO2014159248A1 (en) 2013-03-14 2014-10-02 Newlink Genetics Corporation Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization
PE15942015A1 (en) 2013-03-15 2015-11-19 Squibb Bristol Myers Co Indoleamine dioxygenase inhibitors 2-3
WO2014150677A1 (en) 2013-03-15 2014-09-25 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase (ido)
EP3016932B1 (en) 2013-07-01 2019-02-27 Bristol-Myers Squibb Company Ido inhibitors
CA2917964A1 (en) 2013-07-11 2015-01-15 Bristol-Myers Squibb Company Ido inhibitors

Also Published As

Publication number Publication date
US9388191B2 (en) 2016-07-12
CN105111210B (en) 2018-10-09
ES2660831T3 (en) 2018-03-26
IL241846A (en) 2016-06-30
AU2012242871C1 (en) 2017-02-02
US9260434B2 (en) 2016-02-16
RU2017107026A (en) 2019-01-23
EP3348558A1 (en) 2018-07-18
AU2014274564B2 (en) 2016-10-06
PL2697227T3 (en) 2016-09-30
SMT201600130B (en) 2016-07-01
CL2013002990A1 (en) 2014-07-04
BR112013026494A2 (en) 2016-12-27
AU2012242871B2 (en) 2014-09-11
AU2018202706A1 (en) 2018-05-10
JP2016029092A (en) 2016-03-03
CO6862146A2 (en) 2014-02-10
WO2012142237A8 (en) 2012-11-22
AU2012242871A1 (en) 2013-10-31
SI2697227T1 (en) 2016-06-30
WO2012142237A1 (en) 2012-10-18
AU2012242871A8 (en) 2013-11-21
IL246515A (en) 2018-08-30
RU2013150811A (en) 2015-05-20
RS56992B1 (en) 2018-05-31
JP2014511876A (en) 2014-05-19
AU2016277574A1 (en) 2017-01-12
PE10232018A1 (en) 2018-06-27
NZ616457A (en) 2015-05-29
US9850248B2 (en) 2017-12-26
US20140066625A1 (en) 2014-03-06
SI3018132T1 (en) 2018-04-30
US10233190B2 (en) 2019-03-19
KR20140059167A (en) 2014-05-15
AU2014274564A1 (en) 2015-01-22
US20180118753A1 (en) 2018-05-03
EP2697227B1 (en) 2016-02-03
CN105111210A (en) 2015-12-02
JP6145491B2 (en) 2017-06-14
US20160002249A1 (en) 2016-01-07
PT3018132T (en) 2018-03-09
EP3018132A1 (en) 2016-05-11
MX2013012021A (en) 2014-07-10
RS54723B1 (en) 2016-08-31
ME02417B (en) 2016-09-20
RU2613579C2 (en) 2017-03-17
CY1117440T1 (en) 2017-04-26
MX340442B (en) 2016-07-08
DK2697227T3 (en) 2016-04-25
HUE027316T2 (en) 2016-10-28
RU2017107026A3 (en) 2019-01-23
DK3018132T3 (en) 2018-03-12
HK1223371A1 (en) 2017-07-28
CA2833296A1 (en) 2012-10-18
IL241846D0 (en) 2015-11-30
HRP20180335T1 (en) 2018-04-20
LT3018132T (en) 2018-03-26
HUE038586T2 (en) 2018-10-29
NZ723271A (en) 2018-03-23
NZ708090A (en) 2016-12-23
PE11242014A1 (en) 2014-09-06
HRP20160369T1 (en) 2016-06-03
HK1193822A1 (en) 2017-04-13
US20160362412A1 (en) 2016-12-15
EP2697227A1 (en) 2014-02-19
IL228862A (en) 2015-10-29
JP5837673B2 (en) 2015-12-24
EP3018132B1 (en) 2017-12-13
JP2015061877A (en) 2015-04-02
PL3018132T3 (en) 2018-05-30
JP2017149769A (en) 2017-08-31
CN103547579A (en) 2014-01-29
NO2694640T3 (en) 2018-03-17
AU2016277574B2 (en) 2018-04-19
ES2569665T3 (en) 2016-05-12
CN103547579B (en) 2017-02-15

Similar Documents

Publication Publication Date Title
MX2014012695A (en) Isoindolone derivatives.
PH12014501561B1 (en) Therapeutically active compounds and their methods of use
TW201305107A (en) Substituted benzene compounds
BR112015021999A2 (en) indoleamine 2,3-dioxygenase inhibitors (acid)
MX2015010880A (en) Combination of vaccination and inhibition of the pd-1 pathway.
MX2016002544A (en) Compounds useful as immunomodulators.
IL228745D0 (en) Aryl-or heteroaryl-substituted benzene compunds
SG174883A1 (en) Fused ring inhibitors of hepatitis c
TW201329071A (en) Heterocyclic inhibitors of glutaminase
MX2015007997A (en) Histone demethylase inhibitors.
TW201204714A (en) New compounds
WO2014062720A3 (en) Methods of treating cancer
BR112013026494A2 (en) compound, pharmaceutical composition, method of treating a condition
TW201300375A (en) Heterocyclic autotaxin inhibitors and uses thereof
TW201623221A (en) Compounds useful as immunomodulators
MX2014014765A (en) Macrocyclic inhibitors of flaviviridae viruses.
MX345928B (en) Therapeutically active compositions and their methods of use.
MY166557A (en) Quinazoline derivatives for the treatment of viral infections and further diseases
SG185798A1 (en) Combination therapy methods for treating proliferative diseases
TW201906825A (en) And methods of using compound
PH12016500024A1 (en) Bromodomain inhibitor
EA201490814A1 (en) Treatment of cancer tor-kinase inhibitors
TW201333004A (en) New compounds
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
SI3023415T1 (en) Inhibitors of histone demethylases

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed